These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 27494036)
1. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Henriques De Figueiredo B; Fortpied C; Menis J; Lefebvre JL; Barzan L; de Raucourt D; Geoffrois L; Giurgea L; Hupperets P; Leemans CR; Licitra L; Rolland F; Tesselaar M; Vermorken JB; Grégoire V; Eur J Cancer; 2016 Sep; 65():109-12. PubMed ID: 27494036 [TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417 [TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221 [TBL] [Abstract][Full Text] [Related]
4. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ; Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050 [TBL] [Abstract][Full Text] [Related]
5. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. Forastiere AA; Zhang Q; Weber RS; Maor MH; Goepfert H; Pajak TF; Morrison W; Glisson B; Trotti A; Ridge JA; Thorstad W; Wagner H; Ensley JF; Cooper JS J Clin Oncol; 2013 Mar; 31(7):845-52. PubMed ID: 23182993 [TBL] [Abstract][Full Text] [Related]
6. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800 [TBL] [Abstract][Full Text] [Related]
7. Selection of therapeutic treatment with alternating chemoradiotherapy for larynx preservation in laryngeal carcinoma patients. Ijichi K; Hanai N; Kawakita D; Ozawa T; Suzuki H; Hirakawa H; Kodaira T; Murakami S; Hasegawa Y Jpn J Clin Oncol; 2014 Nov; 44(11):1063-9. PubMed ID: 25187666 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517 [TBL] [Abstract][Full Text] [Related]
9. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy. Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178 [TBL] [Abstract][Full Text] [Related]
10. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI; Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556 [TBL] [Abstract][Full Text] [Related]
12. Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. Su X; He C; Tang T; Chen W; Li Z; Chen Y; Yang A Am J Otolaryngol; 2017; 38(1):52-56. PubMed ID: 27825651 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Altundag O; Gullu I; Altundag K; Yalcin S; Ozyar E; Cengiz M; Akyol F; Yucel T; Hosal S; Sozeri B Head Neck; 2005 Jan; 27(1):15-21. PubMed ID: 15515158 [TBL] [Abstract][Full Text] [Related]
14. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report. Karp DD; Vaughan CW; Carter R; Willett B; Heeren T; Calarese P; Zeitels S; Strong MS; Hong WK Am J Clin Oncol; 1991 Aug; 14(4):273-9. PubMed ID: 1713738 [TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Dietz A; Rudat V; Dreyhaupt J; Pritsch M; Hoppe F; Hagen R; Pfreundner L; Schröder U; Eckel H; Hess M; Schröder M; Schneider P; Jens B; Zenner HP; Werner JA; Engenhardt-Cabillic R; Vanselow B; Plinkert P; Niewald M; Kuhnt T; Budach W; Flentje M Eur Arch Otorhinolaryngol; 2009 Aug; 266(8):1291-300. PubMed ID: 18972123 [TBL] [Abstract][Full Text] [Related]
16. Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents. Furusaka T; Matsuda A; Tanaka A; Matsuda H; Ikeda M Acta Otolaryngol; 2013 Mar; 133(3):318-26. PubMed ID: 23153059 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and Wichmann G; Krüger A; Boehm A; Kolb M; Hofer M; Fischer M; Müller S; Purz S; Stumpp P; Sabri O; Dietz A; Kluge R Eur J Cancer; 2017 Feb; 72():144-155. PubMed ID: 28033526 [TBL] [Abstract][Full Text] [Related]
18. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Guadagnolo BA; Haddad RI; Posner MR; Weeks L; Wirth LJ; Norris CM; Sullivan CA; Goguen L; Busse PM; Tishler R Am J Clin Oncol; 2005 Aug; 28(4):371-8. PubMed ID: 16062079 [TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors. Bozec A; Benezery K; Ettaiche M; Chamorey E; Vandersteen C; Dassonville O; Poissonnet G; Riss JC; Hannoun-Lévi JM; Chand ME; Leysalle A; Saada E; Guigay J; Sudaka A; Demard F; Santini J; Peyrade F Eur Arch Otorhinolaryngol; 2016 Oct; 273(10):3299-306. PubMed ID: 26858198 [TBL] [Abstract][Full Text] [Related]
20. Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx. Chen AM; Hsu S; Meshman J; Chin R; Beron P; Abemayor E; St John M Head Neck; 2017 Jul; 39(7):1322-1326. PubMed ID: 28301066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]